Pharmacological Method To Accelerate Bone Fracture Healing
Award last edited on: 5/3/11

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
J Patrick O'Connor

Company Information

Accelalox Inc

325 Sharon Park Drive Suite 310
Menlo Park, CA 94025
   (650) 854-1465
Location: Single
Congr. District: 18
County: San Mateo

Phase I

Contract Number: 1R43AR058094-01A1
Start Date: 8/5/10    Completed: 7/31/11
Phase I year
Phase I Amount
Bone fractures are common traumatic injuries that often cause temporary disability. In healthy children and adults, fractures normally heal without sequelae, though the temporary disability can lead to muscle atrophy, rehabilitation, and lost time from the work place. Advancing age and other co-morbid conditions, such as diabetes, can greatly increase fracture healing times and reduce overall rates for successful healing. In addition, severe muscle atrophy and prolonged stays at hospitals and rehabilitation or nursing homes are especially common in elderly and diabetic patients. A 25% reduction in healing time would reduce complications and enable people to return to their normal routines much sooner, while dramatically reducing costs associated with healing. Thus a therapy that would accelerate the normal healing process would be of significant benefit to many of the 10 million Americans who suffer a fracture each year. Presently, no such therapy exists. We previously demonstrated that loss or inhibition of COX-2 severely impairs fracture healing. Our tests to understand the mechanism of this impairment led us to test the effects of 5-lipoxygenase (5-LO) inhibitors on the rate of fracture healing. This was based on the idea that when COX-2 is inhibited, arachidonic acid is shunted into the 5-LO pathway and the resulting metabolites slow fracture healing, as detailed in the Background section of this proposal. Following this idea, we have identified a 5-LO inhibitor (A-79175) that reduces the time for fracture healing in rats by 25%, reduced non-unions to 0% from 33% at the experimental endpoint, and increased measures of healed bone strength by 50-90% compared to untreated controls. We have developed a use patent estate for this compound and 5-LO inhibitors in general for bone healing. The composition of matter patent on this compound has lapsed so we can use this compound without having to obtain a license. This compound is a small molecule and is orally available. A-79175 has already successfully passed Phase I human clinical trials for asthma. The half life and other drug-like properties of this molecule, including potency, are well suited for the indication of treating fractures. The aim of this proposal is to demonstrate that A-79175 will accelerate and enhance fracture healing in a higher animal model. A positive finding in this animal model will support the use of 5-LO inhibitors as a therapeutic strategy for fracture care, position A-79175 for an IND application for proof of concept testing in humans, and move our company toward further successful development of the first drug to enhance the rate of bone healing. Increasing the rate of healing could have a large impact on those with factures by improving patient quality of life, reducing recuperation time, muscle wasting, rehabilitation time, incidence of complications, overall health care costs, and more. , ,

Public Health Relevance:
Project Narrative We have identified an orally delivered drug that accelerates and enhances fracture healing in small animal models. Bone fractures are common traumatic injuries. Complications associated with fractures include delayed healing or failed healing (non-unions) and attending disability and muscle atrophy. Common pathological conditions such as osteoporosis and diabetes increase the incidence of fractures or significantly impair healing. Presently, there is no cost-effective therapy to prospectively treat fractures to reduce time to healing or reduce the incidence of delayed healing or non-union. This project will test our newly identified therapy in a clinically relevant animal model to confirm our previous findings and justify testing in humans.

Thesaurus Terms:
0-11 Years Old;21+ Years Old;5-Lipoxygenase;Administration, Oral;Adult;Adverse Effects;Aged 65 And Over;Ailmentary System;Alimentary System;American;Animal Model;Animal Models And Related Studies;Arachidonate 5-Lipoxygenase;Arachidonate[{..}]oxygen 5-Oxidoreductase;Arachidonic Acid 5-Lipoxygenase;Arachidonic Acids;Asthma;Atrophy, Muscle;Bmp-7;Bmp7;Bone;Bone And Bones;Bone Structure Of Tibia;Bones And Bone Tissue;Breeding;Bronchial Asthma;Cox-2;Cox2;Canine Species;Canis Familiaris;Caring;Child;Child Youth;Children (0-21);Clinic;Clinical;Clinical Trials;Clinical Trials, Unspecified;Common Rat Strains;Development;Diabetes Mellitus;Digestive System;Digestive System (All Sites);Dogs;Drug Administration, Oral;Drugs;Elderly;Elderly, Over 65;Fracture;Fracture Healing;Gfac;Gastrointestinal Body System;Growth Agents;Growth Factor;Growth Factors, Proteins;Growth Substances;Hosp;Half-Life;Half-Lifes;Hand;Healed;Healing Abnormal;Healing Delayed;Health Care Costs;Health Costs;Healthcare Costs;Hospitals;Hour;Human;Human, Adult;Human, Child;Human, General;Impaired Healing;Impaired Tissue Repair;Impaired Wound Healing;Impairment;Incidence;Injury;Job Environment;Job Location;Job Place;Job Setting;Job Site;Lta4 Synthase;Lead;Leg;Legal Patent;Length;Leukotriene A Synthase;Leukotriene A4 Synthase;Leukotriene A4 Synthetase;Licensing;Lipoxygenase Inhibitors;Mammals, Dogs;Mammals, Rats;Mammals, Rodents;Man (Taxonomy);Man, Modern;Marketing;Measures;Medical;Medication;Methods;Modeling;Muscle;Muscle Tissue;Muscular Atrophy;Nursing Homes;Op-1;Op-1 Protein;Op1;Oral Administration;Organ System, Gastrointestinal;Orthopedic;Orthopedic Surgical Profession;Orthopedics;Osteogenic Protein 1;Osteoporosis;Osteotomy;Pgg/Hs;Pghs-2;Phs-2;Ptgs2;Ptgs2 Gene;Patents;Pathway Interactions;Patients;Pb Element;Pharmaceutic Preparations;Pharmaceutical Preparations;Pharmacology;Phase;Physical Health Services / Rehabilitation;Physicians;Position;Positioning Attribute;Process;Property;Property, Loinc Axis 2;Qol;Quality Of Life;Radial;Rat;Rattus;Rehabilitation;Rehabilitation Therapy;Rehabilitation, Medical;Research;Research Design;Rodent;Rodentia;Rodentias;Sbir;Sbirs (R43/44);Small Business Innovation Research;Small Business Innovation Research Grant;Speed;Speed (Motion);Study Type;Testing;Therapeutic;Tibia;Time;Treatment Side Effects;Work;Work Location;Work Place;Work-Site;Workplace;Worksite;Abnormal Tissue Repair;Adult Human (21+);Advanced Age;Arm;Base;Bone;Bone Fracture;Bone Healing;Bone Morphogenetic Protein 7;Bone Strength;Canine;Children;Clinical Investigation;Clinical Relevance;Clinically Relevant;Cost;Delayed Wound Healing;Diabetes;Diabetic Patient;Disability;Domestic Dog;Drug/Agent;Economic Impact;Effective Therapy;Elders;Gastrointestinal System;Geriatric;Hcox-2;Healing;Heavy Metal Pb;Heavy Metal Lead;Improved;Innovate;Innovation;Innovative;Intraoral Drug Delivery;Late Life;Later Life;Model Organism;Nursing Home;Older Adult;Older Person;Pathway;Preclinical Study;Public Health Relevance;Recombinant Human Bone Morphogenetic Protein-2;Rehabilitative;Rhbmp-2;Senior Citizen;Side Effect;Small Molecule;Study Design;Therapy Adverse Effect;Tibia;Treatment Adverse Effect;Wasting;Work Environment;Work Setting;Youngster

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
Phase II Amount